GeNeuro SA (GNRO):企業の財務・戦略的SWOT分析

◆英語タイトル:GeNeuro SA (GNRO) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH256252FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥84,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥126,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GeNeuro SA (GeNeuro) operates as a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develops therapeutic products for neurological disorders such as multiple sclerosis, schizophrenia and other diseases of the nervous system. The company offers therapeutic monoclonal antibodies to neutralize the immunopathogenic multiple sclerosis associated RetroViral element envelope proteins detected in MS brain plaques. It develops therapeutics for nervous system pathologies involving human endogenous retroviruses. GeNeuro is headquartered in Geneva, Switzerland.

GeNeuro SA Key Recent Developments

Apr 06,2021: GeNeuro Reports 2020 Full-Year Results and Provides Corporate Update
Mar 02,2021: GeNeuro’s Temelimab Phase 2 Multiple Sclerosis Trial Cleared to Continue Following Planned Data Safety Monitoring Board Meeting
Oct 19,2020: GeNeuro: Financial information and business update for the third quarter 2020
Sep 29,2020: GeNeuro reports 2020 half-year results and provides corporate update
Apr 27,2020: GeNeuro: Financial information and business update for the first quarter 2020

This comprehensive SWOT profile of GeNeuro SA provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of GeNeuro SA including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

GeNeuro SA – Key Information
GeNeuro SA – Overview
GeNeuro SA – Key Employees
GeNeuro SA – Key Employee Biographies
GeNeuro SA – Key Operational Heads
GeNeuro SA – Major Products and Services
GeNeuro SA – History
GeNeuro SA – Company Statement
GeNeuro SA – Locations And Subsidiaries
GeNeuro SA
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

GeNeuro SA – Business Description
GeNeuro SA – Corporate Strategy
GeNeuro SA – SWOT Analysis
SWOT Analysis – Overview
GeNeuro SA – Strengths
GeNeuro SA – Weaknesses
GeNeuro SA – Opportunities
GeNeuro SA – Threats
GeNeuro SA – Key Competitors

Section 3 – Company Financial Performance Charts

GeNeuro SA – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

GeNeuro SA, Key Information
GeNeuro SA, Key Ratios
GeNeuro SA, Share Data
GeNeuro SA, Major Products and Services
GeNeuro SA, History
GeNeuro SA, Key Employees
GeNeuro SA, Key Employee Biographies
GeNeuro SA, Key Operational Heads
GeNeuro SA, Other Locations
GeNeuro SA, Subsidiaries
GeNeuro SA, Key Competitors
GeNeuro SA, SWOT Analysis
GeNeuro SA, Ratios based on current share price
GeNeuro SA, Annual Ratios
GeNeuro SA, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[GeNeuro SA (GNRO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aegean Marine Petroleum Network Inc (ANW):企業の財務・戦略的SWOT分析
    Aegean Marine Petroleum Network Inc (ANW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Clearside BioMedical Inc (CLSD):企業の財務・戦略的SWOT分析
    Summary Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise Uveitis, macular edema associated with non- infectious uveitis; RVO - Retinal Vein Occlu …
  • Mochida Pharmaceutical Co Ltd (4534):製薬・医療:M&Aディール及び事業提携情報
    Summary Mochida Pharmaceutical Co Ltd (Mochida) is a pharmaceutical company that develops, manufactures and markets drugs and diagnostic regents. The company's drugs are used for the treatment of arteriosclerosis obliterans, hyperlipidemia, hypertension, angina pectoris, endometriosis, mycosis, thro …
  • Mesoblast Ltd (MSB):製薬・医療:M&Aディール及び事業提携情報
    Summary Mesoblast Ltd (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft ve …
  • J.Crew Group, Inc.:企業の戦略・SWOT・財務分析
    J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Austin Industries, Inc.:企業の戦略・SWOT・財務情報
    Austin Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Austin Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Seres Therapeutics Inc (MCRB):企業の財務・戦略的SWOT分析
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …
  • Takenaka Corporation:企業の戦略・SWOT・財務情報
    Takenaka Corporation - Strategy, SWOT and Corporate Finance Report Summary Takenaka Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Savara Inc (SVRA):医療機器:M&Aディール及び事業提携情報
    Summary Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include M …
  • La-Z-Boy Inc (LZB):企業の財務・戦略的SWOT分析
    La-Z-Boy Inc (LZB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Lumenis Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Lumenis Ltd (Lumenis), a subsidiary of XIO Group, is an energy-based medical device company for aesthetic, surgical and ophthalmic applications in the field of minimally invasive clinical solutions. It manufactures and distributes medical and aesthetic lasers and light-based systems. Its maj …
  • AFC Energy plc (AFC):企業の財務・戦略的SWOT分析
    Summary AFC Energy Plc (AFC Energy) is a developer of alkaline fuel cells. The company's projects include Power-Up and Alkammonia. AFC Energy power generation technology is used in the industrial markets and produces heat, water, and electricity. The company provides its electricity for industrial a …
  • Vitasoy International Holdings Ltd (0345)
    Vitasoy International Holdings Ltd (0345) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Pharmathen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析
    Summary Pharmathen Pharmaceuticals SA (Pharmathen) is a healthcare products provider that develops and markets generic products. The company’s products include oral antiplatelet agent, bactericidal cephalosporin antibiotic, retinoid, beta1-selective adrenergic receptor blocking agent, and others. It …
  • Servair:企業の戦略・SWOT・財務情報
    Servair - Strategy, SWOT and Corporate Finance Report Summary Servair - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Royal Mail plc:企業の戦略・SWOT・財務分析
    Royal Mail plc - Strategy, SWOT and Corporate Finance Report Summary Royal Mail plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Transgenomic Inc (TBIO)-医療機器分野:企業M&A・提携分析
    Summary Transgenomic Inc (Transgenomic) is a developer and provider of diagnostic tools and services. The company’s products include ICEme Kits, and genetic assays and platforms. It offers genetic assays and platforms such as PCR reagents, chromatography, genetic analysis kits, hanabi cytogenetic sy …
  • Lea County Electric Cooperative Inc:企業の発電所・SWOT分析2018
    Lea County Electric Cooperative Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Strand Life Sciences Pvt Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Strand Life Sciences Pvt Ltd (Strand Life) is a healthcare technology company that develops offers bioinformatics and clinical diagnostic software products. The company offers bioinformatics software for most analytics platforms such as microarrays, mass spectrometry, next generation sequenc …
  • ZAPPALLAS, Inc. (3770):企業の財務・戦略的SWOT分析
    ZAPPALLAS, Inc. (3770) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆